Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Budesonide turbuhaler for asthma

Article Abstract:

The first dry-powder oral inhaler for treatment of asthma is being marketed by Astra under the name Pulmicort Turbuhaler. The active ingredient, budesonide, a corticosteroid, has previously been available as a nasal spray for allergic rhinitis. Other corticosteroids for asthma come in metered dose inhalers which use a propellant. The Turbuhaler is powered by the inhaled breath and seems to deliver twice as much of the drug to the lungs as a propellant-powered metered dose device.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1998
Innovations, Drug delivery systems, Dosage and administration, Antiasthmatic agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Zileuton for asthma

Article Abstract:

The FDA has approved zileuton for the treatment of asthma. Sold under the trade name Zyflo, the drug belongs to a class of drugs called leukotriene inhibitors. Leukotrienes are an inflammatory chemical produced from arachidonic acid. Zileuton inhibits this process. It has been shown to be effective in preventing exacerbations of asthma. Unfortunately, the drug can damage the liver, so children who take it must be monitored for liver damage.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1997
Evaluation, Product/Service Evaluation, Zyflo (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Omalizumab (Xolair): an ani-IgE antibody for asthma

Article Abstract:

Omalizumab (Xolair) is for use by paients at least 12 years old with moderate to severe persistent asthma, which is inadequately controlled by corticosteroid inhalers. The humanized monoclonal anti-IgE antibody drug given subcutaneously reduces the number of asthma exacerbations. It is FDA approved and not cost-effective for all users.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2003
United States, Surgical Appliance and Supplies Manufacturing, Surgical and medical instruments, Inhalators, Usage, Corticosteroids, Adrenocortical hormones, Drug use, Inhalers, Anti-antibodies, Corticosteroid drugs

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, Asthma
Similar abstracts:
  • Abstracts: Gene therapy for cancer. 'Antineoplastons': an unproved cancer therapy. Secrecy in medical research
  • Abstracts: New causes for new diseases. Clean water at low cost. A checklist of hazards
  • Abstracts: Organizational change required for paradigmatic shift in addiction treatment. Avoiding the quality assurance boondoggle in drug treatment programs through total quality management
  • Abstracts: Which peak flow meter? Asthma: peak flow meters. The insider's view
  • Abstracts: Immune function and neuropsychological performance in HIV-1-infected homosexual men. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.